FDC Limited Secures U.S.FDA ANDA Approval for Cefixime Oral Suspension

FDC Limited Secures U.S.FDA ANDA Approval for Cefixime Oral Suspension​

FDC Limited has successfully received ANDA approval from the United States Food and Drug Administration (U.S.FDA). The approval covers Cefixime for Oral Suspension USP.

The FDA approval allows the company to market the suspension in two specific strengths: 100 mg / 5 mL and 200 mg / 5 mL. This material development milestone marks a significant achievement for FDC Limited in the pharmaceutical sector.

FDC Stock Price Movement​

As of 12:20 PM, shares of FDC Limited are slipping by 0.89% in live trading, currently trading at ₹362.90. The stock continues to draw significant attention, with 78,002 shares having been traded in the market thus far.

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.